Articles for tag: antipsychotic, Approval Schizophrenia FDA, Bristol Myers, Bristol myers Squibb, Changer, cholinergic receptors, drug, FDA, FDA approval, game, Karax, mental disorder treatment, mental health treatment, New schizophrenia, nod, schizophrenia, Schizophrenia treatment, sharp, side effects, Therapeutic karuna, years

FDA gives the nod to the first drug Schizophrenia “Game Changer” after 30 years

The US Food and Drug Administration (FDA) approved an innovative drug, Cobenfy (Xanomeline and Trospium Chloride), to treat schizophrenia in adults. Unlike traditional antipsychotic drugs targeting dopamine receptors, Cobenfy focuses on cholinergic receptors, offering a new approach to management of this impairment. Schizophrenia, a serious chronic disease, affects about 1% of the American population and is one of the top 15 causes of disability worldwide. The disorder is known for causing psychotic symptoms such as illusions, illusions and reduced thinking, significantly affecting the quality of life. In Pakistan and worldwide, schizophrenia is a serious concern, with patients often facing social